Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer

doi:10.3760/cma.j.cn371439-20231109-00028

Abstract

Abstract:

The high intra- and inter-tumor heterogeneity of gastric cancer leads to a great difference in the immunotherapy efficacy and the prognosis among patients. Several biomarkers， including programmed death-ligand 1， human epidermal growth factor receptor 2， the features of tumor microenvironment， the peripheral blood inflammatory markers and Claudin18.2 have predictive value in the immunotherapy efficacy and the prognosis of gastric cancer patients， which might help the clinicians find the potential patients who will benefit from immunotherapy， and achieve the goal of precision medicine.

Key words: Stomach neoplasms, Immunotherapy, Forecasting, Biomarkers, tumor, Prognosis

Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.

References 36

[1]	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791. DOI: 10.1097/CM9.0000000000001474.
[2]	Chen M, Li C, Sun M, et al. Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies[J]. Front Immunol, 2022, 13: 1043517. DOI: 10.3389/fimmu.2022.1043517.
[3]	Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. DOI: 10.1016/S0140-6736(21)00797-2. pmid: 34102137
[4]	Xu JM, Jiang H, Pan Y, et al. LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase Ⅲ study[J]. Ann Oncol, 2021, 32: S1331. DOI: 10.1016/j.annonc.2021.08.2133.
[5]	Gao Y, Li S, Xu D, et al. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T_1-4N₊M₀ gastric adenocarcinoma[J]. Chin J Cancer, 2017, 36(1): 61. DOI: 10.1186/s40880-017-0226-3.
[6]	Park Y, Koh J, Na HY, et al. PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs[J]. Cancer Res Treat, 2020, 52(3): 661-670. DOI: 10.4143/crt.2019.718. pmid: 32019283
[7]	Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer[J]. Gastric Cancer, 2015, 18(3): 476-484. DOI: 10.1007/s10120-014-0402-y. pmid: 25038874
[8]	Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial[J]. Lancet, 2023, 402(10418): 2197-2208. DOI: 10.1016/S0140-6736(23)02033-0. pmid: 37871604
[9]	Lian J, Zhang G, Zhang Y, et al. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance[J]. Dig Liver Dis, 2022, 54(10): 1419-1427. DOI: 10.1016/j.dld.2022.01.128.
[10]	Catenacci DVT, Kang YK, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial[J]. Lancet Oncol, 2020, 21(8): 1066-1076. DOI: 10.1016/S1470-2045(20)30326-0.
[11]	Triulzi T, Forte L, Regondi V, et al. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy[J]. Oncoimmunology, 2018, 8(1): e1512942. DOI: 10.1080/2162402X.2018.1512942.
[12]	Yagi S, Wakatsuki T, Yamamoto N, et al. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer[J]. Gastric Cancer, 2019, 22(3): 518-525. DOI: 10.1007/s10120-018-0887-x. pmid: 30328533
[13]	Park SR, Park YS, Ryu MH, et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: results of GASTric cancer HER2 reassessment study 1 (GASTHER1)[J]. Eur J Cancer, 2016, 53: 42-50. DOI: 10.1016/j.ejca.2015.09.018. pmid: 26693898
[14]	Seo S, Ryu MH, Park YS, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)[J]. Gastric Cancer, 2019, 22(3): 527-535. DOI: 10.1007/s10120-018-0891-1. pmid: 30386954
[15]	Choi S, Park S, Kim H, et al. Gastric cancer: mechanisms, biomarkers, and therapeutic approaches[J]. Biomedicines, 2022, 10(3): 543. DOI: 10.3390/biomedicines10030543.
[16]	Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18): 4557-4566. DOI: 10.1158/0008-5472.CAN-18-3962. pmid: 31350295
[17]	Tian C, Jing H, Wang C, et al. Prognostic role of tumour-infiltrating lymphocytes assessed by H&E-stained section in gastric cancer: a systematic review and meta-analysis[J]. BMJ Open, 2021, 11(1): e044163. DOI: 10.1136/bmjopen-2020-044163.
[18]	吴杨, 陈雨琪, 石通国, 等. 胃癌患者免疫微环境中表型特征及其与临床病理参数和预后的关系[J]. 中华医学杂志, 2023, 103(35): 2786-2794. DOI: 10.3760/cma.j.cn112137-20230314-00394.
[19]	Mori T, Tanaka H, Suzuki S, et al. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer[J]. Cancer Sci, 2021, 112(5): 1746-1757. DOI: 10.1111/cas.14888.
[20]	He W, Zhang D, Liu H, et al. The high level of tertiary lymphoid structure is correlated with superior survival in patients with advanced gastric cancer[J]. Front Oncol, 2020, 10: 980. DOI: 10.3389/fonc.2020.00980. pmid: 32733793
[21]	Yin YX, Ling YH, Wei XL, et al. Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients[J]. Front Immunol, 2022, 13: 973085. DOI: 10.3389/fimmu.2022.973085.
[22]	Jiang Q, Tian C, Wu H, et al. Tertiary lymphoid structure patterns predicted anti-PD1 therapeutic responses in gastric cancer[J]. Chin J Cancer Res, 2022, 34(4): 365-382. DOI: 10.21147/j.issn.1000-9604.2022.04.05.
[23]	Lugli A, Zlobec I, Berger MD, et al. Tumour budding in solid cancers[J]. Nat Rev Clin Oncol, 2021, 18(2): 101-115. DOI: 10.1038/s41571-020-0422-y.
[24]	Xue C, Du Y, Li Y, et al. Tumor budding as a predictor for prognosis and therapeutic response in gastric cancer: a mini review[J]. Front Oncol, 2022, 12: 1003959. DOI: 10.3389/fonc.2022.1003959.
[25]	Zhang N, Wang D, Duan Y, et al. The special immune microenvironment of tumor budding and its impact on prognosis in gastric adenocarcinoma[J]. Pathol Res Pract, 2020, 216(6): 152926. DOI: 10.1016/j.prp.2020.152926.
[26]	Ulase D, Heckl S, Behrens HM, et al. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the international tumour budding consensus conference[J]. Histopathology, 2020, 76(3): 433-446. DOI: 10.1111/his.13997. pmid: 31538348
[27]	Szalai L, Jakab Á, Kocsmár I, et al. Prognostic ability of tumor budding outperforms poorly differentiated clusters in gastric cancer[J]. Cancers (Basel), 2022, 14(19): 4731. DOI: 10.3390/cancers14194731.
[28]	Piersma B, Hayward MK, Weaver VM. Fibrosis and cancer: a strained relationship[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(2): 188356. DOI: 10.1016/j.bbcan.2020.188356.
[29]	Aurello P, Berardi G, Giulitti D, et al. Tumor-stroma ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients[J]. Surgeon, 2017, 15(6): 329-335. DOI: 10.1016/j.surge.2017.05.007.
[30]	Kim EY, Abdul-Ghafar J, Chong Y, et al. Calculated tumor-associated neutrophils are associated with the tumor-stroma ratio and predict a poor prognosis in advanced gastric cancer[J]. Biomedicines, 2022, 10(3): 708. DOI: 10.3390/biomedicines10030708.
[31]	Qu Z, Wang Q, Wang H, et al. The effect of inflammatory markers on the survival of advanced gastric cancer patients who underwent anti-programmed death 1 therapy[J]. Front Oncol, 2022, 12: 783197. DOI: 10.3389/fonc.2022.783197.
[32]	Chen Y, Zhang C, Peng Z, et al. Association of lymphocyte-to-monocyte ratio with survival in advanced gastric cancer patients treated with immune checkpoint inhibitor[J]. Front Oncol, 2021, 11: 589022. DOI: 10.3389/fonc.2021.589022.
[33]	Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet, 2023, 401(10389): 1655-1668. DOI: 10.1016/S0140-6736(23)00620-7. pmid: 37068504
[34]	Rohde C, Yamaguchi R, Mukhina S, et al. Comparison of claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma[J]. Jpn J Clin Oncol, 2019, 49(9): 870-876. DOI: 10.1093/jjco/hyz068. pmid: 31087075
[35]	Sahin U, Türeci Ö, Manikhas G, et al. FAST: a randomised phase Ⅱ study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma[J]. Ann Oncol, 2021, 32(5): 609-619. DOI: 10.1016/j.annonc.2021.02.005. pmid: 33610734
[36]	Gao J, Wang Z, Jiang W, et al. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation[J]. J Immunother Cancer, 2023, 11(6): e006704. DOI: 10.1136/jitc-2023-006704.